Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced Intensity Haploidentical HSCT with NK Cell Infusion for Pediatric Cancer
NCT00582816Phase 2Terminated
- Sponsor
- University of Wisconsin–Madison
- Start
- Aug 2008
- Primary completion
- Aug 2015
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of NK cell therapy (Anhui Provincial Hospital) in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), solid tumor, sponsored by University of Wisconsin–Madison. Started Aug 2008; status: terminated.
02
Drugs
NK cell therapy (Anhui Provincial Hospital)
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)solid tumor
Beyond the preview
Go deeper on NCT00582816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00582816.